Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWAKHD)

Drug Name

GNF-PF-3464 Drug Info

Synonyms

GNF-Pf-3464; MLS000080647; SMR000035446; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile; AC1LDF42; MLS002584786; cid_666034; CHEMBL602213; BDBM54721; MolPort-002-638-170; HMS2390G20; CCG-29223; STK849599; AKOS001814539; AKOS022041133; MCULE-2552432292; SR-01000096914; SR-01000096914-1; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-3,4,7,8-tetrahydro-2H,6H-pyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 666034
TTD Drug ID: DMWAKHD
VARIDT Drug ID: DR01045

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[3]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[1]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[4]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[5]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[6]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[7]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[8]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[9]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Hepatitis C virus NS3 helicase (HCV NS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-9451	DMF910Q	Chronic HCV-1 infection	1E51.1	Phase 2	[11]
GS-9857	DMYU6P5	Hepatitis C virus infection	1E51.1	Phase 2	[12]
BILN-2061	DM2J36F	Hepatitis virus infection	1E50-1E51	Phase 2	[13]
VBY-376	DMU263R	Hepatitis C virus infection	1E51.1	Phase 1	[14]
ACH-2684	DMW6X0O	Hepatitis C virus infection	1E51.1	Phase 1	[15]
BMS-605339	DMY7ZRA	Hepatitis C virus infection	1E51.1	Terminated	[16]
AcAsp-D-Gla-Leu-Ile-Cha-Cys	DMT74F5	Discovery agent	N.A.	Investigative	[17]
Cbz-Ile-Leu-L-(difluoro)aminobutyric acid	DMI53WR	Discovery agent	N.A.	Investigative	[17]
AcGlu-Dif-Ile-Cha-Cys	DMK6HGI	Discovery agent	N.A.	Investigative	[18]
AcGlu-Dif-Glu-Cha-Cys	DM0BV9I	Discovery agent	N.A.	Investigative	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus NS3 helicase (HCV NS3)	TTWXB3E	POLG_HCV1	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2	Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
3	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
4	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
5	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
6	Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
7	N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
8	CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
9	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
10	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
11	Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
12	Clinical pipeline report, company report or official report of Gilead.
13	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
14	Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
15	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
16	Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
17	Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
18	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.